Swift Observations of GRB 050603: An afterglow with a steep late time decay slope

We report the results of Swift observations of the Gamma Ray Burst GRB 050603. With a V magnitude V=18.2 about 10 hours after the burst the optical afterglow was the brightest so far detected by Swift and one of the brightest optical afterglows ever seen. The Burst Alert Telescope (BAT) light curves show three fast-rise-exponential-decay spikes with $T_{90}$=12s and a fluence of 7.6$\times 10^{-6}$ ergs cm$^{-2}$ in the 15-150 keV band. With an $E_{\rm \gamma, iso} = 1.26 \times 10^{54}$ ergs it was also one of the most energetic bursts of all times. The Swift spacecraft began observing of the afterglow with the narrow-field instruments about 10 hours after the detection of the burst. The burst was bright enough to be detected by the Swift UV/Optical telescope (UVOT) for almost 3 days and by the X-ray Telescope (XRT) for a week after the burst. The X-ray light curve shows a rapidly fading afterglow with a decay index $\alpha$=1.76$^{+0.15}_{-0.07}$. The X-ray energy spectral index was $\beta_{\rm X}$=0.71\plm0.10 with the column density in agreement with the Galactic value. The spectral analysis does not show an obvious change in the X-ray spectral slope over time. The optical UVOT light curve decays with a slope of $\alpha$=1.8\plm0.2. The steepness and the similarity of the optical and X-ray decay rates suggest that the afterglow was observed after the jet break. We estimate a jet opening angle of about 1-2$^{\circ}$Comment: 14 pages, accepted for publication in Ap

Family-Focused Treatment for Adolescents and Young Adults at High Risk for Psychosis: Results of a Randomized Trial

Objective: Longitudinal studies have begun to clarify the phenotypic characteristics of adolescents and young adults at clinical high risk for psychosis. This 8-site randomized trial examined whether a 6-month program of family psychoeducation was effective in reducing the severity of attenuated positive and negative psychotic symptoms and enhancing functioning among individuals at high risk. Method: Adolescents and young adults (mean age 17.4 +/- 4.1 years) with attenuated positive psychotic symptoms, brief and intermittent psychosis, or genetic risk with functional deterioration were randomly assigned to 18 sessions of family-focused therapy for individuals at clinical high risk (FFT-CHR) in 6 months or 3 sessions of family psychoeducation (enhanced care [EC]. FFT-CHR included psychoeducation about early signs of psychosis, stress management, communication training, and problem-solving skills training, whereas EC focused on symptom prevention. Independent evaluators assessed participants at baseline and 6 months on positive and negative symptoms and social-role functioning. Results: Of 129 participants, 102 (79.1%) were followed up at 6 months. Participants in FFT-CHR showed greater improvements in attenuated positive symptoms over 6 months than participants in EC (F-1,F-97 = 5.49, p = .02). Negative symptoms improved independently of psychosocial treatments. Changes in psychosocial functioning depended on age: participants more than 19 years of age showed more role improvement in FFT-CHR, whereas participants between 16 and 19 years of age showed more role improvement in EC. The results were independent of concurrent pharmacotherapy. Conclusion: Interventions that focus on improving family relationships may have prophylactic efficacy in individuals at high risk for psychosis. Future studies should examine the specificity of effects of family intervention compared to individual therapy of the same duration and frequency. Clinical trial registration information-Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis

The p53 codon 72 PRO/PRO genotype may be associated with initial central visual field defects in Caucasians with primary open angle glaucoma

Background: Loss of vision in glaucoma is due to apoptotic retinal ganglion cell loss. While p53 modulates apoptosis, gene association studies between p53 variants and glaucoma have been inconsistent. In this study we evaluate the association between a p53 variant functionally known to influence apoptosis (codon 72 Pro/Arg) and the subset of primary open angle glaucoma (POAG) patients with early loss of central visual field. Methods: Genotypes for the p53 codon 72 polymorphism (Pro/Arg) were obtained for 264 POAG patients and 400 controls from the U.S. and in replication studies for 308 POAG patients and 178 controls from Australia (GIST). The glaucoma patients were divided into two groups according to location of initial visual field defect (either paracentral or peripheral). All cases and controls were Caucasian with European ancestry. Results: The p53-PRO/PRO genotype was more frequent in the U.S. POAG patients with early visual field defects in the paracentral regions compared with those in the peripheral regions or control group (p = 2.761025). We replicated this finding in the GIST cohort (p = 7.361023, and in the pooled sample (p = 6.661027) and in a meta-analysis of both the US and GIST datasets (1.361026, OR 2.17 (1.58–2.98 for the PRO allele). Conclusions: These results suggest that the p53 codon 72 PRO/PRO genotype is potentially associated with early paracentral visual field defects in primary open-angle glaucoma patients.NHMRC: This study was supported by National Institutes of Health/National Eye Institute grants: R01EY015872 (Wiggs), R01EY015473 (Pasquale), P30EY014104 (Wiggs), Research to Prevent Blindness (Wiggs, Pasquale, Realini), the Harvard Glaucoma Center of Excellence (Wiggs, Pasquale), The Massachusetts Lions Eye Research Fund (Wiggs, Pasquale), National Health & Medical Research Council Project grant 229960, the Ophthalmic Research Institute of Australia, and Glaucoma Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

A knowledge-based framework for service management

peer-reviewedThe purpose of this paper is to investigate how information and communication technologies are used for service standardisation, customisation, and modularisation by knowledge-intensive service firms through the development and empirical validation of a knowledge-based framework. This paper uses 59 in-depth interviews, observational data, and document analysis from case studies of three service-related departments in high-technology, multinational knowledge-intensive business services (KIBSs). Prior research does not conceptualise the relationships between service customisation, standardisation and modularisation. This paper seeks to overcome this gap by integrating insights from research on the role played by both knowledge and information and communication technologies (ICTs) to construct and validate a framework to deal with this gap. It outlines the implications for service firms' use of ICT to deal with increasing knowledge intensity as well as indicating the circumstances under which service knowledge is best customised, standardised and modularised. Further testing in other industries would prove useful in extending the usefulness and applicability of the findings. The originality of the paper lies in developing and validating the first framework to outline the relationship between how service knowledge is customised, standardised or modularised and indicating the associated issues and challenges. It emphasises the role of knowledge and technology. The value of this framework increases as more firms deal with increasing knowledge intensity in the services they provide and in their use of ICTs to reap the benefits of appropriate knowledge reuse.ACCEPTEDpeer-reviewe

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial

Background Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line therapy. However, the majority of patients relapse and require further therapy, and so new, effective, targeted therapies that improve remission rates, reduce relapses, and have fewer side effects, are required. The FLAIR trial will assess whether ibrutinib plus rituximab (IR) is superior to FCR in terms of progression-free survival (PFS). Methods/design FLAIR is a phase III, multicentre, randomised, controlled, open, parallel-group trial in patients with previously untreated CLL. A total of 754 participants will be randomised on a 1:1 basis to receive standard therapy with FCR or IR. Participants randomised to FCR will receive a maximum of six 28-day treatment cycles. Participants randomised to IR will receive six 28-day cycles of rituximab, and ibrutinib taken daily for 6 years until minimal residual disease (MRD) negativity has been recorded for the same amount of time as it took to become MRD negative, or until disease progression. The primary endpoint is PFS according to the International Workshop on CLL (IWCLL) criteria. Secondary endpoints include: overall survival; proportion of participants with undetectable MRD; response to therapy by IWCLL criteria; safety and toxicity; health-related quality of life (QoL); and cost-effectiveness. Discussion The trial aims to provide evidence for the future first-line treatment of CLL patients by assessing whether IR is superior to FCR in terms of PFS, and whether toxicity rates are favourable. Trial registration ISRCTN01844152. Registered on 8 August 2014, EudraCT number 2013-001944-76. Registered on 26 April 2013

Enhancing Woodbury’s Urban Tree Canopy

Report completed by students enrolled in FNRM 4501/5501 - Urban Forest Management: Managing Greenspaces for People, taught by Dr. Eric North in Spring 2021.This project was completed as part of a partnership between the City of Woodbury, the Metropolitan Council, and the University of Minnesota’s Resilient Communities Project (http://www.rcp.umn.edu). The goal of this project was to provide recommendations on how the City can equitably increase its tree canopy coverage and update its approved tree species list. City of Woodbury project lead Kristin Seaman collaborated with students in Eric North’s course, FNRM 4501/5501 - Urban Forest Management: Managing Greenspaces for People, to assess Woodbury's current tree canopy, investigate how it could be equitably expanded in the future, and provide analysis and recommendations for the City to incorporate into their updated tree canopy plan. Final student reports and presentations are available. A videorecording of the students' final presentation is also available at https://vimeo.com/547699038.This project was supported by the Resilient Communities Project (RCP), a program at the University of Minnesota whose mission is to connect communities in Minnesota with U of MN faculty and students to advance community resilience through collaborative, course-based projects. RCP is a program of the Center for Urban and Regional Affairs (CURA). More information at http://www.rcp.umn.edu. Additional funding and support was provided by the Metropolitan Council of the Twin Cities

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

Background: Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different treatment approaches and regardless of the line of therapy. Methods/design: GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) is a seamless phase II/III, multi-centre, randomised, controlled, open, parallel-group trial for patients with CLL who have recently responded to chemotherapy. Participants will be randomised to receive either obinutuzumab (GA-101) consolidation or no treatment (as is standard). The phase II trial will assess safety and short-term efficacy in order to advise on continuation to a phase III trial. The primary objective for phase III is to assess the effect of consolidation therapy on progression-free survival (PFS). One hundred eighty-eight participants are planned to be recruited from forty research centres in the United Kingdom. Discussion: There is evidence that achieving MRD eradication with alemtuzumab consolidation is associated with improvements in survival and time to progression. This trial will assess whether obinutuzumab is safe in a consolidation setting and effective at eradicating MRD and improving PFS. Trial registration: ISRCTN, 64035629. Registered on 12 January 2015. EudraCT, 2014-000880-42. Registered on 12 November 2014

Assessing the assessments: Evidencing and benchmarking student learning outcomes in chemistry

Background Higher Education in Australia is in a phase of rapid change due to a number of regulatory changes. Over the past five years the Australian Chemistry community has agreed on a list of Chemistry Threshold Learning Outcomes (CTLOs) that every student graduating from an Australian University will have attained. In addition, the Royal Australian Chemical Institute (RACI) has changed its accreditation process for Chemistry degrees and now uses these CTLOs as the basis for accreditation. Therefore, it is now paramount to ensure that our assessment items allow students to demonstrate attainment of the CTLOs during a degree (Elmgren, Ho, Åkesson, Schmid & Towns 2015). The “Assessing the Assessments” project, funded by the Australian Government’s Office for Learning and Teaching (OLT ID14-3562) is developing a framework designed to help academics at tertiary institutions to determine the alignment of their assessment items with the CTLOs. The project is also collating a database of exemplary standards-based assessment items. Outcomes The project team has developed an online pro-forma, allowing self-assessment and submission of assessment items. Through workshops, colleagues are guided through a deeper evaluation of assessment items to determine how they meet or fall short of attainment of specific CTLOs. These workshops are designed to support evaluation of assessment items to ensure that they are CTLO compliant, using a tool developed over the course of the project. Results of evaluations conducted using this tool provide information regarding which portions of each CTLO students engage with through the task’s design, the level of scope and complexity at which they are engaged and the extent to which the attainment of each CTLO is assessed. Results also reveal which features of the CTLOs may need to be assessed more explicitly or rigorously in order to confirm student attainment or otherwise. References Elmgren, M., Ho, F., Åkesson, E., Schmid S. & Towns, M. J. Chem. Educ. 92, 427- 432 (2015). Comparison and evaluation of learning outcomes from an international perspective: Development of a best-practice process. Proceedings of the Australian Conference on Science and Mathematics Education, The University of Queensland, Sept 28th to 30th, 2016, page X, ISBN Number 978-0-9871834-4-6

Assessment of learning outcomes workshop: How do you know that your assessment tasks are effective?

Background Higher Education in Australia is in a phase of rapid change due to regulatory changes (TEQSA) and a shift towards a standards based framework. Over the past five years, the Chemistry community in Australia has developed the Chemistry Threshold Learning Outcomes (CTLOs) which articulate the outcomes that every student graduating from an Australian university with a major in Chemistry will have attained. In keeping with this development, the Royal Australian Chemical Institute (RACI) now bases its accreditation for Chemistry degrees on the CTLOs. Therefore, it is now vital to the Chemistry community to ensure that the assessment items we use allow students to demonstrate attainment of all CTLOs during their chemistry degree. Our OLT funded project (Assessing the assessments: Evidencing and benchmarking student learning outcomes in Chemistry (OLT ID14-3562)) has developed a diagnostic framework that will help you to determine whether your assessment items actually deliver reliable measures of student performance and provide evidence of achievement of the CTLOs. An additional outcome of the project will be a database of standards-based assessment items to be shared with the Chemistry community. Workshop Format We invite you to attend this half-day workshop where project team members will guide you through evaluating your assessment items for their ‘fitness for purpose’ in providing evidence of achievement of the CTLOs. Ideally you will bring along one of your 2nd or 3rd year Chemistry assessment items (in electronic format) so that the workshop team can guide you through an online submission and evaluation to determine: 1. Which CTLOs are explicitly demonstrated by students through successful completion of the item? 2. Is your task suited to a developing or graduate level understanding? 3. To what extent can your task be said to help confirm student attainment of the CTLOs? A critical aspect of this process is consideration of marking schemes and student work for the assessment items. We strongly encourage you to bring one or two pieces of marked pass level student work (de-identified) that can be used to evidence successful attainment of a particular CTLO. A central part of the workshop will be a ‘calibration’ exercise, which allows developing a mutual understanding of what constitutes demonstrating attainment of a particular CTLO. While the content of this workshop is Chemistry specific, the process is not. Therefore we are confident that all ACSME attendees will find this to be a valuable experience. All are invited. Attendance is free, however, registration is required for catering purposes. Proceedings of the Australian Conference on Science and Mathematics Education, The University of Queensland, Sept 28th to 30th, 2016, page X, ISBN Number 978-0-9871834-4-6

Swift XRT Observations of the Afterglow of GRB 050319

Swift discovered the high redshift GRB 050319 with the Burst Alert Telescope and began observing with its narrow field instruments only 225 s after the burst onset. The afterglow X-ray emission was monitored by the XRT up to 28 days after the burst. The light curve shows a decay with three different phases, each characterized by a distinct slope: an initial steep decay with a power law index of ~ 5.5, a second phase characterized by a flat decay slope of \~ 0.54, and a third phase with a decay slope of ~ 1.14. During the first phase the spectral energy distribution is softer than in the following two phases and the photon index is consistent with the GRB prompt spectrum. The extrapolation of the BAT light curve to the XRT band suggests that the initial fast decaying phase of the XRT afterglow might be the low energy tail of the prompt emission. The second break in the afterglow light curve occurs about 27000 s after the burst. The spectral energy distribution before and after the second break does not change and it can be tentatively interpreted as a jet break or the end of a delayed or continuous energy injection phase.Comment: 15 pages, 2 figures. Accepted for publication in Ap